Nasdaq 100 2026 YTD Highs & Lows Radar: AMGEN (AMGN), Electronic Arts, (EA) and more
MarketsFN Team
Nasdaq 100 2026 YTD Highs & Lows Radar: AMGEN (AMGN), Electronic Arts, (EA) and more
Screening all 101 Nasdaq 100 constituents for stocks nearest to their 2026 year-to-date high and their 2026 YTD low. Data as of September 04, 2026. % Realized = total return since Jan 1 2026.
Legend: RSI > 70 = overbought · RSI < 30 = oversold · Green % Realized = positive YTD return · Red = negative.
📈 Nearest to 2026 High
Sectors represented: Healthcare (3), Technology (1), Communication Services (1)
| Ticker | Company | Sector | Price Last | % Realized | 2026 YTD High Date | RSI | % above MA200 | Trend |
|---|---|---|---|---|---|---|---|---|
| AMGN | AMGEN Inc | Healthcare | $444.12 | +35.55% | 2026-09-03 | 64.6 | +23.9% | Above MA20, MA50, MA200 |
| VRTX | Vertex Pharmaceuticals, Inc | Healthcare | $557.96 | +23.41% | 2026-09-03 | 65.2 | +19.7% | Above MA20, MA50, MA200 |
| TEAM | Atlassian Corporation | Technology | $194.68 | +25.79% | 2026-09-03 | 68.6 | +78.2% | Above MA20, MA50, MA200 |
| EA | Electronic Arts, Inc | Communication Services | $209.70 | +0.38% | 2026-08-04 | — | — | — |
| BIIB | Biogen Inc | Healthcare | $224.51 | +26.26% | 2026-09-03 | 60.8 | +17.5% | Above MA20, MA50, MA200 |
AMGN | AMGEN Inc | Healthcare | Price Last: $444.12 | % Realized: +35.55% | RSI: 64.6 | % above MA200: +23.9% | Trend: Above MA20, MA50, MA200
AMGEN Inc is a biotechnology company that develops and markets human therapeutics, focusing on innovative treatments for serious illnesses such as cancer, cardiovascular disease, and bone health disorders, making it an attractive investment for those seeking exposure to the biotech sector.
AMGN's current technical situation indicates sustained uptrend momentum with price > MA20 > MA50 > MA200, RSI(14) at 64.6, and a 35.6% 2026 YTD return, near its YTD high, suggesting potential for further breakout.
Related headlines
VRTX | Vertex Pharmaceuticals, Inc | Healthcare | Price Last: $557.96 | % Realized: +23.41% | RSI: 65.2 | % above MA200: +19.7% | Trend: Above MA20, MA50, MA200
Vertex Pharmaceuticals, Inc is a biotechnology company that develops and commercializes treatments for cystic fibrosis and other serious diseases. Investors should care because its cystic fibrosis treatments have shown significant market success and the company continues to expand its pipeline.
Vertex Pharmaceuticals shows bullish technicals with RSI(14) at 65.2, indicating rising momentum, and a sustained uptrend as price ($554.92) remains above MA20 > MA50 > MA200. The stock is near its 2026 YTD high, up 23.4% YTD, suggesting potential for further breakout.
Related headlines
- Vertex Completes $10 Billion Crinetics Acquisition, Adding Rare Endocrine Growth Platform
- Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team
- Vertex to Participate in Upcoming September Investor Conferences
- Vertex Stock Jumps 5.9% as Rival Cystic Fibrosis Drug Fails
TEAM | Atlassian Corporation | Technology | Price Last: $194.68 | % Realized: +25.79% | RSI: 68.6 | % above MA200: +78.2% | Trend: Above MA20, MA50, MA200
Atlassian Corporation is a software company that provides collaboration and productivity tools like Jira and Trello. Investors should care because its products are widely adopted, and its financial performance is tied to the growing demand for digital collaboration solutions.
Atlassian's current technical situation indicates strong momentum: RSI(14) is 68.6, and the stock is in a sustained uptrend with price > MA20 > MA50 > MA200. It's near its 2026 YTD high, 0.0% below, suggesting a potential breakout.
Related headlines
EA | Electronic Arts, Inc | Communication Services | Price Last: $209.70 | % Realized: +0.38% | RSI: — | % above MA200: — | Trend: —
Electronic Arts, Inc (EA) is a video game company that develops and publishes games such as FIFA and Madden NFL. Investors should care because its performance is tied to the gaming industry's growth and popularity of its flagship titles.
The stock is near its 2026 YTD high, up 0.4% YTD. Since MA data is incomplete and RSI(14) is N/A, we cannot assess momentum or MA alignment. The proximity to its YTD high may indicate a potential breakout.
BIIB | Biogen Inc | Healthcare | Price Last: $224.51 | % Realized: +26.26% | RSI: 60.8 | % above MA200: +17.5% | Trend: Above MA20, MA50, MA200
Biogen Inc is a biotechnology company that develops treatments for neurological diseases, such as multiple sclerosis and Alzheimer's. Investors should care because its therapies address significant unmet medical needs, potentially driving revenue growth.
Biogen's current technical situation indicates momentum, with RSI(14) at 60.8 and a bullish MA alignment (price > MA20 > MA50 > MA200). The stock is near its 2026 YTD high, up 26.3% YTD, suggesting sustained uptrend.
Related headlines
- Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
- Stoke Therapeutics and Biogen to present four-year zorevunersen data at epilepsy congress
- Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
- Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation
📉 Nearest to 2026 Low
Sectors represented: Communication Services (1), Healthcare (1), Industrials (1), Consumer Defensive (1), Utilities (1)
| Ticker | Company | Sector | Price Last | % Realized | 2026 YTD Low Date | RSI | % above MA200 | Trend |
|---|---|---|---|---|---|---|---|---|
| EA | Electronic Arts, Inc | Communication Services | $209.70 | +0.38% | 2026-07-17 | — | — | — |
| IDXX | Idexx Laboratories, Inc | Healthcare | $529.29 | -21.00% | 2026-06-30 | 36.6 | -12.8% | Below MA20, MA50, MA200 |
| HON | Honeywell International Inc | Industrials | $207.63 | +1.07% | 2026-01-02 | 31.8 | -9.6% | Below MA20, MA50, MA200 |
| PEP | PepsiCo Inc | Consumer Defensive | $140.02 | -1.55% | 2026-07-23 | 43.1 | -5.9% | Above MA50 · Below MA20, MA200 |
| EXC | Exelon Corp | Utilities | $44.53 | +1.39% | 2026-01-12 | 42.3 | -3.1% | Below MA20, MA50, MA200 |
EA | Electronic Arts, Inc | Communication Services | Price Last: $209.70 | % Realized: +0.38% | RSI: — | % above MA200: — | Trend: —
Electronic Arts, Inc (EA) is a video game company that develops and publishes games such as FIFA and Madden NFL. Investors should care because its performance is tied to the gaming industry's growth and popularity of its flagship titles.
The stock is near its 2026 YTD high, up 0.4% YTD. Since MA data is incomplete and RSI(14) is N/A, we cannot assess momentum or MA alignment. The proximity to its YTD high may indicate a potential breakout.
IDXX | Idexx Laboratories, Inc | Healthcare | Price Last: $529.29 | % Realized: -21.00% | RSI: 36.6 | % above MA200: -12.8% | Trend: Below MA20, MA50, MA200
Idexx Laboratories, Inc is a veterinary diagnostics and software company, providing testing and consulting services. Investors should care due to its market leadership and growth potential in the pet healthcare industry.
IDXX's technicals indicate a sustained downtrend with price < MA20 < MA50 < MA200, RSI(14) at 36.6, and a 2026 YTD low proximity of 0.5%, warning of potential further decline, with a -21.0% 2026 YTD return.
Related headlines
- IDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
- IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test
- IDEXX Laboratories, Inc. Q2 2026 Earnings Call Summary
- IDEXX Laboratories Inc (IDXX) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and ...
HON | Honeywell International Inc | Industrials | Price Last: $207.63 | % Realized: +1.07% | RSI: 31.8 | % above MA200: -9.6% | Trend: Below MA20, MA50, MA200
Honeywell International Inc is a diversified technology conglomerate that operates in various sectors including aerospace, building technologies, and performance materials. Investors should care due to its broad industrial exposure and innovation-driven growth prospects.
Honeywell's current technical situation indicates a sustained downtrend with price at $207.83 below all key MAs (MA20, MA50, MA200) and an RSI(14) of 31.8, suggesting potential oversold conditions as it tests major support 1.1% above its 2026 YTD low.
Related headlines
- Honeywell Technologies Announces Participation at Upcoming Investor Conference
- Honeywell Aerospace Agrees To Pay Over $2M To Settle Cybersecurity Allegations HONA Stock Falls 2.5%
- Honeywell Aerospace announces participation at upcoming investor conferences
- Honeywell Aerospace Stock Has Fallen Far Enough. Morgan Stanley Says It's Time to Buy.
PEP | PepsiCo Inc | Consumer Defensive | Price Last: $140.02 | % Realized: -1.55% | RSI: 43.1 | % above MA200: -5.9% | Trend: Above MA50 · Below MA20, MA200
PepsiCo Inc is a multinational food and beverage corporation that generates revenue through the sale of popular brands like Pepsi, Lay's, and Gatorade, making it a significant player in the consumer staples sector, with investors drawn to its stable demand and dividend yield.
PepsiCo Inc's current technical situation indicates a warning sign, with an RSI(14) of 43.1, below MA20/MA50/MA200, and only 3.8% above its 2026 YTD low, suggesting testing of major support, and a -1.6% return over the 2026 YTD period.
Related headlines
EXC | Exelon Corp | Utilities | Price Last: $44.53 | % Realized: +1.39% | RSI: 42.3 | % above MA200: -3.1% | Trend: Below MA20, MA50, MA200
Exelon Corp (EXC) is a utility company that generates and distributes electricity, operating nuclear, natural gas, and renewable energy facilities. Investors care about its stable cash flows and dividend yield, given its role in meeting US energy demands.
EXC's technicals indicate a sustained downtrend with price ($44.12) below MA20, MA50, and MA200. The RSI(14) is 42.3, nearing oversold territory. The stock is 3.8% above its 2026 YTD low, testing major support, with a 1.4% return over the 2026 YTD period.
Related headlines
- Exelon Announces Key Leadership Position Changes
- Exelon Secures More Than $1 Billion in Customer Protections Through Pioneering Transmission Security Agreements
- Exelon high probability data center load falls 40%
- Exelon Corp (EXC) (Q2 2026) Earnings Call Highlights: Navigating Regulatory Hurdles and Data ...
Market Commentary
The Nasdaq 100 stocks listed are near their 2026 year-to-date (YTD) extremes, with some at their highs and others at their lows. Stocks like AMGN, VRTX, TEAM, EA, and BIIB are at their 2026 YTD highs, indicating strong performance, while EA, IDXX, HON, PEP, and EXC are near their 2026 YTD lows, suggesting weaker performance.
The technology sector themes driving these moves may be related to the strong performance of biotech and software companies, as seen in the stocks at their 2026 YTD highs. Macro conditions, such as interest rates and economic growth, may also be influencing investor sentiment. The presence of EA in both lists suggests that some stocks are experiencing high volatility.
Investors and traders should watch the performance of these stocks and the overall Nasdaq 100 index for signs of trend continuation or reversal. Key factors to monitor include earnings reports, industry trends, and broader economic indicators. The current positioning of these stocks near their 2026 YTD extremes may indicate a significant shift in market sentiment, making it essential to stay informed and adapt to changing market conditions.
Methodology: All 101 Nasdaq 100 constituents screened. Close prices downloaded from 2026-01-01. Period high = highest close since Jan 1 2026; period low = lowest close since Jan 1 2026. Distance = (current price / period extreme − 1) × 100. Technical indicators computed on up to 1 year of daily OHLCV data.
Disclaimer: For informational purposes only. Not investment advice. Past performance is not indicative of future results.
